Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
暂无分享,去创建一个
B. Clotet | J. Martinez-Picado | T. Wrin | J. Prado | S. Frost | C. Petropoulos | L. Ruiz | R. D’Aquila | Jeff Beauchaine | R. D'Aquila | L. Ruíz
[1] V. Johnson,et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group , 1993, Antimicrobial Agents and Chemotherapy.
[2] D Norbeck,et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.
[3] R. Myers,et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.
[4] E D Blair,et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.
[5] M. Murcko,et al. Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .
[6] B. Sadler,et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. , 1996, Antiviral research.
[7] David J. Livingston,et al. Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants* , 1996, The Journal of Biological Chemistry.
[8] R. Colonno,et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[9] D. Lamarre,et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.
[10] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[11] Dale J. Kempf,et al. In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor , 1998, Journal of Virology.
[12] M. Markowitz,et al. Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.
[13] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.
[14] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[15] S. Gulnik,et al. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. , 1999, AIDS.
[16] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[17] D. Kuritzkes,et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. , 1999, The Journal of infectious diseases.
[18] C. Boucher,et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. , 1999, AIDS.
[19] J. Martinez-Picado,et al. Human Immunodeficiency Virus Type 1 Cloning Vectors for Antiretroviral Resistance Testing , 1999, Journal of Clinical Microbiology.
[20] K. Hertogs,et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure , 2000, AIDS.
[21] Christos J. Petropoulos,et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.
[22] R. Myers,et al. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. , 2000, AIDS research and human retroviruses.
[23] J. Martinez-Picado,et al. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. , 2000, Virology.
[24] B. Schmidt,et al. Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease Inhibitors , 2000, Antimicrobial Agents and Chemotherapy.
[25] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[26] Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. , 2001, The Journal of infectious diseases.